The consulting firm McKinsey & Company has entered into a deferred prosecution agreement with the U.S. Justice Department, a resolution that carries a $650 million financial penalty and a formal criminal designation. The charge against the firm is conspiracy to misbrand a drug, stemming directly from its advisory work for Purdue Pharma on the marketing of OxyContin.
Obstruction of justice allegations are also part of the case. This is not a civil penalty but a criminal resolution, marking a significant moment for a company that has long cultivated an image of discretion and strategic excellence. Founded in 1926 by James O. McKinsey, the firm expanded into Europe during the 1940s and 1950s under Marvin Bower, establishing itself as a premier management consultant.
Its clientele has included governments, multinational corporations, and institutions central to the global economy. The Purdue Pharma engagement now represents a permanent blemish on that legacy.
The Justice Department’s case focuses on advice McKinsey provided that was intended to increase sales of a highly addictive painkiller. The firm’s recommendations prioritized revenue growth, with public health considerations appearing secondary. The opioid crisis has resulted in hundreds of thousands of American deaths, and OxyContin is widely cited as a key contributor to that epidemic.
McKinsey’s role was to assist Purdue in selling more of the drug. While the $650 million payment is substantial, it represents an operational expense for a firm that generates billions of dollars in annual revenue.
The deferred prosecution agreement allows McKinsey to avoid a criminal trial, provided it meets the conditions set by the Justice Department, including cooperation. This cooperation could be seen as a step toward accountability or as a strategic move to protect the firm’s franchise. The case raises broader questions about the consulting industry.
McKinsey is the oldest and largest of the “MBB” firms, which also include Boston Consulting Group and Bain & Company. These firms sell strategy and the premise that rigorous analysis can resolve any corporate challenge.
The Purdue case suggests that such analysis can also be applied to problematic objectives. A former McKinsey partner, Fred Gluck, once spoke of transforming corporate strategies. The firm’s current circumstances cast that idea in a darker light.
The willingness to pay $650 million and accept a criminal resolution indicates the firm recognizes the stakes. The brand has suffered damage, and the question is whether it is permanent.
Other consulting firms will observe the outcome closely. The Justice Department has signaled that professional services firms are not exempt from criminal liability for the advice they provide. This marks a notable shift.
For years, consultants operated in a gray area, offering recommendations while clients made final decisions. The Purdue case removes that shield.
Advising a client to break the law can make the advisor part of the conspiracy. McKinsey’s future is uncertain. The firm will likely restructure its compliance and risk-management functions and review its client acceptance policies. It may lose some clients wary of the association, or gain others who see a tested firm.
The deferred prosecution agreement buys time, but questions about ethics and responsibility remain. The opioid crisis did not start with McKinsey, but the firm’s role in accelerating OxyContin sales worsened it.
The $650 million settlement is a price for that role. Whether it changes behavior is another matter. The consulting industry has long assumed that advice is just advice.
The Justice Department has now made clear that advice can be a crime.
